Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Santen Launches Tafluprost in South Korea
May 24, 2010
- Proper Use of Topical Steroids Should Be Promoted: Prof. Horio
May 24, 2010
- Daiichi Sankyo Voluntarily Recalls Amplit Tablets 25 mg
May 24, 2010
- Erbitux Makes Hepatic Metastasis of Colon Cancer Curable: Prof. Sugihara
May 24, 2010
- Need for Biosimilars Highlighted at CPhI 2010 Panel Discussion
May 24, 2010
- Cervarix Shows Immunological Responses Significantly Higher Than Gardasil: Dr Einstein
May 24, 2010
- Joji Nakayama to Be Appointed President of Daiichi Sankyo
May 24, 2010
- Teva-Kowa to Integrate Taisho Pharm's Marketing Division in July
May 24, 2010
- Cervarix Offers “Excellent Protection”for Japanese Women As Well: Prof. Konno
May 24, 2010
- Takeda: Sales Down 4.7% Due to Patent Expiration for Lansoprazole in the US
May 24, 2010
- Kissei to Launch Japan's 1st EPO Biosimilar
May 24, 2010
- Santen Licenses ATL313 from Clinical Data
May 17, 2010
- Peptide Vaccine Therapy for Bladder Cancer Recommended for Conditional Approval
May 17, 2010
- Kissei Licenses Proaerolysin from Protox
May 17, 2010
- Package Inserts for DPP-4 Inhibitors, GLP-1 Analogue to Be Modified
May 17, 2010
- Takeda Settles Actos Patent Infringement Litigations in US
May 17, 2010
- Reimbursement Method to Be Reviewed for 23 Products
May 17, 2010
- Korosho's Growth Strategy Calls For Development of New Drugs, Medical Devices
May 17, 2010
- LDP, JPMA Exchange Opinions on How to Promote Clinical Trials in Japan
May 17, 2010
- Korosho, METI Set Up Joint Task Force to Promote New Growth Strategy
May 17, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…